Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits

British Journal of Pharmacology

Volumn 172, Issue 5, 2015, Pages 1237-1249

  Nakagami, Yasuhiro ^a   Masuda, Kayoko ^a   Hatano, Emiko ^a   Inoue, Tatsuya ^a   Matsuyama, Takuya ^a   Iizuka, Mayumi ^a   Ono, Yasunori ^a   Ohnuki, Takashi ^a   Murakami, Yoko ^a   Iwasaki, Masaru ^a   Yoshida, Kazuhiro ^a   Kasuya, Yuji ^a   Komoriya, Satoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; BARDOXOLONE METHYL; FUMARIC ACID DIMETHYL ESTER; GLYCOSYLATED ALBUMIN; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RS 10; RS 11; RS 12; RS 14; RS 8; RS 9; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR NRF2 ACTIVATOR; UNCLASSIFIED DRUG; GLYCOSYLATED SERUM ALBUMIN; OXYGEN; RS9 TRITERPENOID; SERUM ALBUMIN; TRITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RETINA BARRIER; CELL DAMAGE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INDUCTION; EYE INFLAMMATION; FEMALE; HEPA1C1C7 CELL LINE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; OXYGEN-INDUCED RETINOPATHY; PROTEIN FUNCTION; RABBIT; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PERMEABILITY; RETROLENTAL FIBROPLASIA; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-RETINAL BARRIER; CELL LINE; FEMALE; HUMANS; MALE; MICE; NF-E2-RELATED FACTOR 2; OXYGEN; PERMEABILITY; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RETINOPATHY OF PREMATURITY; SERUM ALBUMIN; TRITERPENES;

EID: 84922830221     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12999     Document Type: Article

References (42)

1. Abboud HE, (2013). Synthetic oleanane triterpenoids: magic bullets or not? Kidney Int 83: 785-787.
2. Age-Related Eye Disease Study 2 Research Group (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309: 2005-2015.
3. Akula JD, Hansen RM, Martinez-Perez ME, Fulton AB, (2007). Rod photoreceptor function predicts blood vessel abnormality in retinopathy of prematurity. Invest Ophthalmol Vis Sci 48: 4351-4359.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
5. Chin MP, Reisman SA, Bakris GL, O'Grady M, Linde PG, McCullough PA, et al. (2014). Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol 39: 499-508.
6. Endo A, Kuroda M, Tsujita Y, (1976). ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot 29: 1346-1348.
7. Fahey JW, Dinkova-Kostova AT, Stephenson KK, Talalay P, (2004). The 'Prochaska' microtiter plate bioassay for inducers of NQO1. Methods Enzymol 382: 243-258.
8. Falavarjani KG, Nguyen QD, (2013). Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27: 787-794.
9. Firuzi O, Miri R, Tavakkoli M, Saso L, (2011). Antioxidant therapy: current status and future prospects. Curr Med Chem 18: 3871-3888.
10. Gao B, Doan A, Hybertson BM, (2014). The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders. Clin Pharmacol 6: 19-34.
11. Hikino H, Nabetani S, Takemoto T, (1969). [Microbial transformation of oleanolic acid. 1]. Yakugaku Zasshi 89: 809-813.
12. Hikino H, Nabetani S, Takemoto T, (1972). [Microbial transformation of oleanolic acid. 4]. Yakugaku Zasshi 92: 1528-1533.
13. Itoh K, Mimura J, Yamamoto M, (2010). Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 13: 1665-1678.
14. Jarrett SG, Boulton ME, (2012). Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med 33: 399-417.
15. Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, et al. (2013). Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 329: 163-177.
16. Kiernan DF, Mieler WF, (2012). Intraocular corticosteroids for posterior segment disease: 2012 update. Expert Opin Pharmacother 13: 1679-1694.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
18. Komoriya S, Nakagami Y, Hatano E, Ohnuki T, Masuda K, Iizuka M, et al. (2013). Tripernoid derivatives. WO2014/148455 A1.
19. Kuno N, Fujii S, (2010). Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging 27: 117-134.
20. Liby KT, Sporn MB, (2012). Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 64: 972-1003.
21. Liby KT, Yore MM, Sporn MB, (2007). Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369.
22. Mactier H, McCulloch DL, Hamilton R, Galloway P, Bradnam MS, Young D, et al. (2012). Vitamin A supplementation improves retinal function in infants at risk of retinopathy of prematurity. J Pediatr 160: 954-959.
23. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
24. Nathan DM, McGee P, Steffes MW, Lachin JM, DCCT/EDIC Research Group (2014). Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 63: 282-290.
25. Nguyen DH, Luo J, Zhang K, Zhang M, (2013). Current therapeutic approaches in neovascular age-related macular degeneration. Discov Med 15: 343-348.
26. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
27. Payne AJ, Kaja S, Naumchuk Y, Kunjukunju N, Koulen P, (2014). Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina. Int J Mol Sci 15: 1865-1886.
28. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336.
29. Ravindran S, Basu S, Surve P, Lonsane G, Sloka N, (2012). Significance of biotransformation in drug discovery and development. J Biotechnol Biomater S13: 005.
30. Reisman SA, Lee CY, Meyer CL, Proksch JW, Sonis ST, Ward KW, (2014). Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis. Radiat Res 181: 512-520.
31. Rushworth SA, MacEwan DJ, O'Connell MA, (2008). Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J Immunol 181: 6730-6737.
32. Serizawa N, Matsuoka T, (1991). A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Biochim Biophys Acta 1084: 35-40.
33. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW, (2011). New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 74: 537-545.
34. Suzuki T, Motohashi H, Yamamoto M, (2013). Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34: 340-346.
35. Venisetty RK, Ciddi V, (2003). Application of microbial biotransformation for the new drug discovery using natural drugs as substrates. Curr Pharm Biotechnol 4: 153-167.
36. Wang L, Kondo N, Cano M, Ebrahimi K, Yoshida T, Barnett BP, et al. (2014). Nrf2 signaling modulates cigarette smoke-induced complement activation in retinal pigmented epithelial cells. Free Radic Biol Med 70: 155-166.
37. Wang Y, Burgess D, (2012). Long acting injections and implants. In:, Wright JC, Burgess D, (eds). Advances in Delivery Science and Technology. Springer: Heidelberg, pp. 167-194.
38. Xu Z, Wei Y, Gong J, Cho H, Park JK, Sung ER, et al. (2014). NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia 57: 204-213.
39. Yasukawa T, Wiedemann P, Hoffmann S, Kacza J, Eichler W, Wang YS, et al. (2007). Glycoxidized particles mimic lipofuscin accumulation in aging eyes: a new age-related macular degeneration model in rabbits. Graefes Arch Clin Exp Ophthalmol 245: 1475-1485.
40. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. (2013). Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369: 2492-2503.
41. Zhang S, Leske DA, Holmes JM, (2000). Neovascularization grading methods in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 41: 887-891.
42. Zhong Q, Mishra M, Kowluru RA, (2013). Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 54: 3941-3948.